



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/697,991	10/30/2003	M. Benjamin Perryman	UTEC:007US	7402

7590 04/21/2005

FULBRIGHT & JAWORSKI L.L.P.  
SUITE 2400  
600 CONGRESS AVENUE  
AUSTIN, TX 78701-3271

EXAMINER
----------

GAKH, YELENA G

ART UNIT	PAPER NUMBER
----------	--------------

1743

DATE MAILED: 04/21/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/697,991

Applicant(s)

PERRYMAN ET AL.

Examiner

Yelena G. Gakh, Ph.D.

Art Unit

1743

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 24 January 2005 and 22 February 2005.
- 2a) ☒ This action is FINAL. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-52 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-52 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

Art Unit: 1743

### DETAILED ACTION

1. Amendment filed 02/22/05 and Affidavit under 37 C.F.R. §1.131 filed 01/24/05 are acknowledged. Claims 1-52 are pending in the application.

#### *Response to Amendment*

2. Rejection of claims 13 and 25 under 35 U.S.C. 112, second paragraph is withdrawn; rejection of the claims over the prior art is partly modified in view of the amendment.

3. The Affidavit filed on 01/24/05 under 37 CFR 1.131 has been considered but is ineffective to overcome the Tubbs reference. Tubbs reference has a priority date of 01/18/2001, rather than 01/15/2002 indicated in the Affidavit.

#### *Claim Rejections - 35 USC § 102*

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

5. **Claims 1-6, 8, 11-13, 18-28, 30, 32, 34, 37-39, 44-52** are rejected under 35 U.S.C. 102(e) as being anticipated by Tubbs et al. (US 2002/0094566 A1) or Gruber et al. (US 2002/0164818).

Tubbs or Gruber teach MALDI-TOF quantitative analysis of complex protein mixtures in biological samples using internal standards (IS), with the following examples

Art Unit: 1743

of the IS indicated: "internal reference standards that behave similarly to the analyte during laser desorption/ionization are generally preferred. This prerequisite is met during MSIA by choosing internal references that share sequence homology with the target protein: enzymatic/chemically-modified versions of the targeted protein, truncated/extended recombinant forms of the target proteins, the (same) target protein recombinantly expressed in isotopically-enriched media (e.g.,  $^{15}\text{N}$  or  $^{18}\text{O}$ ), or the same protein from a different biological species" (page 16, [0157] in Tubbs, Example 4 [0052] on page 5 in Gruber). "As used herein, "biological media" or "biological sample" refers to a fluid or extract having a biological origin. Biological media may be, but are not limited to, cell extracts, nuclear extracts, cell lysates and excretions, blood, sera, plasma, urine, sputum, sinovial fluid, cerebral-spinal fluid, tears, feces, saliva, membrane extracts, and the like" (page 22, [0202]). "FIG. 17b Spectrum in (2) shows EDTA/Ca.sup.2+ affinity pipette capture of two phosphate rich proteins, PRP-1 and PRP 3. Mass signature of dephosphorylation is evident in spectral trace (3) and complete in (4). Illustrating multi-analyte detection accompanied by partial and complete dephosphorylation of phospho-proteins captured/digested out of biological fluid for post-translational analysis (i.e., phosphorylation events" (isoforms in form of phosphoisomers) (page 4, [0038]).

### *Claim Rejections - 35 USC § 103*

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.

Art Unit: 1743

4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
8. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
9. **Claims 7, 9-10, 14-15, 29, 31, 33, 35-36 and 40-41** are rejected under 35 U.S.C. 103(a) as being unpatentable Tubbs or Gruber in view of Forssmann et al. (US 6,326,163 B1).

Tubbs or Gruber do not specifically teach quantification of  $\alpha$ - or  $\beta$ -myosin heavy chain by MALDI-TOF.

Forssmann teaches "a quick method for the qualitative and quantitative medical-diagnostic analysis on the protein level of the substitution of single amino acids with pathogenic and non-pathogenic effects on the organism. The medical-diagnostic analysis is performed by a combination of enzymatic or chemical cleavage of the isolated peptide, chromatographical separation of the fragments and analysis by mass spectrometry, both direct LC/MS and indirect MALDI-MS, and analysis by capillary electrophoresis. By comparing protein samples from healthy humans with those of ill humans, the method described is suitable for establishing new, as yet unknown mutations and quantifying the expression and incorporation of wild type to mutant" (Abstract). The invention is "illustrated by using the heavy chain of  $\beta$ -isoform of myosin as an example. Point mutations in the heavy chain of  $\beta$ -isoform of myosin, e.g., substitution of the amino acid methionine for the amino acid valine in position 606, may result in hypertrophic cardiomyopathy, a genetically caused thickening of certain heart walls, which may lead to sudden death. According to the invention, the detection of the mutation is possible by a combination of enzymatic cleavage and LC/MS. FIGS. 1a and 1b show the analysis of the peptide fragments of human cardiac  $\beta$ -myosin heavy chain ( $\beta$ -MHC) by means of a

Art Unit: 1743

coupling of high performance liquid chromatography (HPLC) with mass spectrometry (MS). In this example, the presence of the heterozygotic mutant Val606Met, i.e., substitution of valin in position 606 of  $\beta$ -MHC, was looked for. FIG. 1a shows two marked ranges in which the fragment with a substituted amino acid and a molecular weight of 1507.5 could be detected in addition to the original fragment, the wild type fragment having a molecular weight of 1475.5, in a person for whom the substitution had been proven on the gene level. For comparison, FIG. 1b shows the analysis of a  $\beta$ -MHC sample of a person with no point mutation in this gene. In this case, only the wild type fragment can be detected; in the range in which the mutated fragment was eluted in FIG. 1a, this peptide is completely lacking. Thus, it becomes possible to detect mutated  $\beta$ -MHC in a person's muscle fibers" (col. 3, lines 1-30).

It would have been obvious for anyone of ordinary skill in the art to apply the method of quantitative measurement of proteins, including their mixtures, by MALDI-TOF analysis using internal standards, as disclosed in the references cited above, to  $\alpha$ - or  $\beta$ -myosin isoforms heavy chains, because Forssmann teaches the importance of quantitative measurements of these proteins for monitoring cardiovascular diseases, and the method disclosed by the references cited above allows to do this in a most efficient way.

10. **Claims 16-17 and 42-43** are rejected under 35 U.S.C. 103(a) as being unpatentable over Tubbs in view of England et al. (Cellular Signalling, 2002).

Tubbs or Gruber do not specifically teach quantification of cardiac or skeletal actin by MALDI-TOF.

England teaches, "proteins coimmunoprecipitating with protein kinase C (PKC)  $\epsilon$  in fibroblasts were identified through matrix-assisted laser desorption/ionisation time of flight mass spectrometry (MALDI TOF m/s). This method identified myosin IIA in PKC  $\epsilon$  immunoprecipitates, as well as known PKC epsilon binding proteins, actin,  $\beta$ Cop and cytokeratin" (Abstract).

It would have been obvious for anyone of ordinary skill in the art to apply the method of quantitative measurement of proteins, including their mixtures, by MALDI-TOF analysis using internal standards, as disclosed in the references cited above, to actin,

Art Unit: 1743

because England indicates the importance of actin as a modulator of PKC activity, which is essential for cellular growth.

### *Response to Arguments*

11. Applicant's arguments filed 02/25/05 have been fully considered but they are not persuasive. Tubbs' reference is not overcome by the Affidavit for the reasons indicated above. Regarding obviousness-type rejections, Forssman discloses MALDI-TOF analysis, although he calls it MALDI-MS: "by using the highly sensitive "matrix-assisted laser-induced desorption and ionization **time-of-flight** mass spectrometry" (MALDI-MS) (col. 1, lines 66-67 and col.2, line 1). England does not need to teach the method of the instant invention applied to cardiac or skeletal actin, as he is not used as a primary or anticipatory reference. Tubbs indicates that his method can be applied to numerous objects with cardiac or skeletal actin disclosed by England as one of them.

### *Conclusion*

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the

Art Unit: 1743


advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yelena G. Gakh, Ph.D. whose telephone number is (571) 272-1257. The examiner can normally be reached on 9:30 am - 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jill A. Warden can be reached on (571) 272-1267. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

4/14/05

  
YELENA GAKH  
PRIMARY EXAMINER